APOE and Alzheimer disease: Among AD patients, cognitive decline is pronounced in APOE4, compared to APOE3 carriers (Emrani et al., 2020; Gharbi-Meliani et al., 2021; Qian et al., 2021, 2023; Polsinelli et al., 2023b).